Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

The S&P 500 Bears Are Getting Started

In yesterday’s flagship Stock Trading Alert, we have evaluated the week just over, and examined the health of the S&P 500 advance. As the S&P 500 declined profoundly yesterday, we’ll revisit the credit markets and one key S&P 500 sector to asses...
Monica Kingsley | April 22, 2020 |

Commercialization Accelerates for POET Technologies’ Platform Technology

At POET Technologies, we have been a company of “-ization”. We had a goal for the “legitimization” of photonics in the semiconductor industry and built a hybrid-integration solution to deliver on the “optimization&CloseCurlyDoub...
Research | March 22, 2023 |

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Earl...
Streetwise Reports | October 18, 2019 |

Augmented Reality Shows Huge Potential for Augmented Gains

Augmented Reality has been the province of behemoths like Amazon and Apple, but a small-cap firm is finding success bringing AR to smaller businesses. NexTec...
Streetwise Reports | May 3, 2019 |

Precision Medicine Firm Announces 'Positive' Data in Lymphoma Study

The highlights of the results were presented in an H.C. Wainwright & Co. report. In a June 14 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Kura Oncology Inc. (KURA:NASDAQ) met the endpoint in its Phase 2 clinical trial of...
Streetwise Reports | June 21, 2019 |

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. After U.S. markets...
Streetwise Reports | January 13, 2020 |

Airbus, BASF, Osino Resources - where is the highest return?

Normally, investors are happy about rising share prices, because the stock market is the expression of the future and expected growth in pricing. However, what has been observed since the outbreak of the Corona Pandemic and the measures that have accompanied it has little to d...
Mario Hose | June 22, 2020 |

Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity

These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. In a June 22 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Targovax ASA's (TRVX:OSE) ONCOS-102, in trial ...
Streetwise Reports | June 25, 2020 |

Why Did ImmunoGen Plummet 32%?

This biotechnology company, which focuses on the treatment of cancer, received some feedback from the FDA that upset investors on Wednesday. ImmunoGen Inc.'s (IMGN:NASDAQ) shares closed down 32.06% on the NASDAQ Wednesday after announcing the United States ...
Streetwise Reports | May 21, 2019 |

Construction Pipeline Shows Undervalued Opportunity

This Vancouver Construction Company Continues to Trade Undervalued with a Long List of Projects in the Pipeline. A Vancouver-based general contracting company, with a list of international jobs in the pipeline, is trading for just eight cents apiece right now. From ea...
Fraser Palamara | March 10, 2021 |
1 2 3 4 5 6 7 8